DCTH:NASDAQ
Delcath Systems Inc
US$10.80
arrow_upward
+4.05%(+0.42) 1 天
US$10.76
arrow_downward
-0.37% (-0.040)today开盘前
休市： 5月1日, GMT-4 16:00:00 · USD
search
所有股票代码
1 天
5 天
1 个月
6 个月
年初至今
1 年
5 年
最大
| 股票代码 | 价格 | 涨跌额 | 涨跌幅 |
|---|
insights_auto正在为 DCTH 生成关键数据洞见…
开盘价
US$10.44
最高价
US$10.83
最低价
US$10.36
市值
三.七二亿
成交量
〇.〇〇
市盈率
一五九.六七
52 周最高价
US$18.23
52 周最低价
US$8.12
每股收益
US$0.07
Beta 版
〇.五四
流通股数
三四四五.五〇万
员工人数
一五六
新闻报道
来自全网
资料
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally. Wikipedia
Delcath Systems Inc简介